Department of Ophthalmology, University of Athens Medical School, 'Attikon' General Hospital Athens, Haidari, Athens, Greece.
Eur J Ophthalmol. 2021 Nov;31(6):2868-2875. doi: 10.1177/11206721211014717. Epub 2021 May 5.
To compare the 1-year outcomes of treat-and-extend and pro re nata (PRN) treatment regimens with aflibercept for polypoidal choroidal vasculopathy (PCV), by the means of visual acuity (VA), frequency of recurrence of polypoidal lesions and developed fibrosis, and the number of intravitreal injections, and thus to determine which one is preferable in the maintenance phase in PCV.
In our prospective study, only naive and previously untreated PCV patients were included. Initially one session of photodynamic therapy (PDT) and three monthly intravitreal injections of 2.0 mg aflibercept (IAIs) were applied in 38 eyes. After this loading phase, they were re-examined and 30 PCV eyes with no exudative phenomena were included in the study. They were divided in two groups; in the first one (16 patients) the PRN treatment modality of IAIs was applied, while in the second one (14 patients) the treat-and-extend regimen was applied.
Over a 12-month period, VA significantly improved in treat-and-extend group (logMAR BCVA 0.41 ± 0.15 vs 0.57 ± 0.24 at baseline, = 0.044), while in the PRN group VA remained stable (logMAR BCVA 0.70 ± 0.36 vs 0.65 ± 0.18 at baseline, = 0.61). During the maintenance phase, the patients of treat-and-extend group did not encounter development/progression of fibrosis or any recurrent episodes, whereas the patients of PRN group had significantly more recurrent episodes (0 vs 1.37 ± 0.5, < 0.001) and the frequency of development/progression of fibrosis was significantly higher (0% vs 44%, = 0.02). However, the treat-and-extend treatment regimen was accompanied by significantly more administered IAIs (6 ± 0 vs 5.13 ± 1.08, = 0.006).
We highlighted the superiority of treat-and-extend regime with IAIs, which seems to yield better functional outcomes by preventing recurrence and subfoveal fibrosis, although a greater number of injections is required.
通过比较治疗和延长与按需(PRN)治疗方案在息肉状脉络膜血管病变(PCV)中的 1 年结果,包括视力(VA)、息肉状病变和纤维化的复发频率以及玻璃体内注射的次数,从而确定在 PCV 的维持阶段哪种方法更可取。
在我们的前瞻性研究中,仅纳入初治和未经治疗的 PCV 患者。最初在 38 只眼中应用了一次光动力疗法(PDT)和三次每月 2.0mg 阿柏西普(IAI)玻璃体内注射。在这个负荷阶段之后,对其进行了重新检查,其中 30 只没有渗出表现的 PCV 眼被纳入研究。他们被分为两组;在第一组(16 名患者)中,应用了 PRN 治疗模式的 IAI,而在第二组(14 名患者)中,应用了治疗和延长方案。
在 12 个月的时间里,治疗和延长组的 VA 显著改善(logMAR BCVA 0.41±0.15 与基线时的 0.57±0.24, = 0.044),而 PRN 组的 VA 保持稳定(logMAR BCVA 0.70±0.36 与基线时的 0.65±0.18, = 0.61)。在维持阶段,治疗和延长组的患者没有出现纤维化的发展/进展或任何复发,而 PRN 组的患者复发次数明显更多(0 与 1.37±0.5, < 0.001),纤维化的发展/进展频率也明显更高(0%与 44%, = 0.02)。然而,治疗和延长治疗方案伴随着明显更多的 IAI 注射(6±0 与 5.13±1.08, = 0.006)。
我们强调了 IAI 治疗和延长方案的优势,它通过防止复发和黄斑下纤维化来获得更好的功能结果,尽管需要更多的注射次数。